secwatch.observer — SEC 8-K summary
======================================

Issuer:     GILEAD SCIENCES, INC. (GILD)
CIK:        0000882095
Form:       8-K
Filed at:   2022-02-01T23:59:59+00:00
Accession:  0001104659-22-010300
Event type: litigation
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02
LLM model:  deepseek-v4-flash:cloud@v2

Gilead settles Biktarvy patent litigation with ViiV for $1.25B upfront + 3% royalty through 2027
--------------------------------------------------------------------------------

- One-time payment of $1.25B to ViiV in Q1 2022; pre-tax charge of $1.25B recorded in Q4 2021.
- Ongoing 3% royalty on U.S. sales of Biktarvy and bictegravir products until October 5, 2027.
- Settlement resolves all pending and potential claims across U.S. and international jurisdictions.
- ViiV grants Gilead a broad worldwide license and covenant not to sue for bictegravir.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882095/000110465922010300/0001104659-22-010300-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882095/000110465922010300/tm224824d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-010300

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer